China-focused Tigermed staves off biopharma gloom
Investors have not been deterred by an earnings slide, wagering that the drugs services company is better placed to weather an industry storm than some biopharma stocks Key Takeaways: Tigermed…
Viva Biotech Revenues Surge on Move Into Contract Drug Manufacturing
Two key acquisitions last fall helped fuel fivefold rise in first-half revenue, as company swung back into profitability Key Takeaways: Viva Biotech’s fivefold jump in first-half revenues and move back…
Newly Merged dMed-Clinipace Turns Up Heat in China’s Booming CRO Market
Company’s new $50 million funding is the first since its April merger, as competition grows among nation’s contract research organizations (CROs) Key points: dMed-Clinipace’s raises $50 million in the…
RELATED ARTICLES
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK -
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK 603259.SHG
-
WuXi Bio prescribes share buyback to relieve revenue pain
2269.HK
-
FAST NEWS: JPMorgan boosts WuXi AppTec stake
2359.HK 603259.SHG
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
- InSilico seeks IPO boost to get AI drugs over the line
